NFATC2 and prostate cancer: In addition, the GEPIA web tool analysis showed that the mRNA levels of NFAT1 (NFATC2) were positively correlated with the expression of PD-L1 (CD274) in ccRCC, lung adenocarcinoma, bladder cancer, liver cancer, prostate cancer, pancreatic cancer, and breast cancer (Fig. 3D, Supplementary Fig. 2A-2F).